Daniel Herchenhorn

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Jun Guo, Richard D. Carvajal, Reinhard Dummer et al. · Annals of Oncology · 2017 · 166 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation

Héliton Spíndola Antunes, Daniel Herchenhorn, I. A. Small et al. · Radiotherapy and Oncology · 2013 · 137 citations

Medicine, Oncology, Radiation Oncology +16

Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis

Héliton Spíndola Antunes, Daniel Herchenhorn, I. A. Small et al. · Oral Oncology · 2017 · 125 citations

Medicine, Oncology, Radiation Oncology +16

Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation

Héliton Spíndola Antunes, Luciene Schluckebier, Daniel Herchenhorn et al. · Oral Oncology · 2015 · 66 citations

Medicine, Oncology, Oncologic Surgery +10

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Angélica Nogueira‐Rodrigues, Claudio Calazan do Carmo, Célia M. Viégas et al. · Clinical Cancer Research · 2008 · 48 citations

Medicine, Oncology, Pharmacology +17